Long term anti-SARS-CoV-2 antibody kinetics and correlate of protection against Omicron BA.1/BA.2 infection

• Published in: Nature communications 2023-05, Vol.14 (1), p.3032-3032, Article 3032
• Main Authors: Perez-Saez, Javier, Zaballa, María-Eugenia, Lamour, Julien, Yerly, Sabine, Dubos, Richard, Courvoisier, Delphine S., Villers, Jennifer, Balavoine, Jean-François, Pittet, Didier, Kherad, Omar, Vuilleumier, Nicolas, Kaiser, Laurent, Guessous, Idris, Stringhini, Silvia, Azman, Andrew S.
• Format: Article
• Language: English
• Subjects: 631/250/24; 631/326/596/4130; 692/308/174; 692/699/255/2514; Antibodies; Antibodies, Neutralizing; Antibodies, Viral; Binding; COVID-19; Humanities and Social Sciences; Humans; Immune Evasion; Immunoassay; Infections; Kinetics; multidisciplinary; Population levels; Reduction; SARS-CoV-2; Science; Science (multidisciplinary); Severe acute respiratory syndrome coronavirus 2; Vaccination
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-023-38744-7

Binding antibody levels against SARS-CoV-2 have shown to be correlates of protection against infection with pre-Omicron lineages. This has been challenged by the emergence of immune-evasive variants, notably the Omicron sublineages, in an evolving immune landscape with high levels of cumulative incidence and vaccination coverage. This in turn limits the use of widely available commercial high-throughput methods to quantify binding antibodies as a tool to monitor protection at the population-level. Here we show that anti-Spike RBD antibody levels, as quantified by the immunoassay used in this study, are an indirect correlate of protection against Omicron BA.1/BA.2 for individuals previously infected by SARS-CoV-2. Leveraging repeated serological measurements between April 2020 and December 2021 on 1083 participants of a population-based cohort in Geneva, Switzerland, and using antibody kinetic modeling, we found up to a three-fold reduction in the hazard of having a documented positive SARS-CoV-2 infection during the Omicron BA.1/BA.2 wave for anti-S antibody levels above 800 IU/mL (HR 0.30, 95% CI 0.22-0.41). However, we did not detect a reduction in hazard among uninfected participants. These results provide reassuring insights into the continued interpretation of SARS-CoV-2 binding antibody measurements as an independent marker of protection at both the individual and population levels. Binding antibody levels correlate with protection against infection with the ancestral SARS-CoV-2 strain, but it is not clear whether this relationship extends to the Omicron variant. Here, the authors characterise antibody dynamics and their relationship with Omicron infection in a longitudinal cohort from Geneva, Switzerland.